Group 1 - The core event is the proposed stock swap merger of China International Capital Corporation (CICC) with Dongxing Securities and Xinda Securities, with CICC as the surviving entity and no additional fundraising involved [1][2] - The merger is expected to significantly enhance CICC's comprehensive strength, with net asset scale projected to increase from 115.5 billion yuan to 171.5 billion yuan, an increase of approximately 56 billion yuan [2] - The merger will complement CICC's capabilities in fixed income, foreign exchange, and brokerage services, potentially increasing the asset scale available for these businesses to between 111.9 billion yuan and 167.9 billion yuan [2] Group 2 - The merger is anticipated to reshape the competitive landscape of the industry, creating a brokerage firm that ranks among the top in asset scale, net capital, and business coverage [3] - The combined strengths of Dongxing Securities and Xinda Securities in network, client base, and capital resources will enhance CICC's investment banking, professional investment, cross-border trading services, and wealth management capabilities [3] - This merger marks a significant step towards establishing a world-class investment bank in China that can compete with international leaders like Goldman Sachs and Morgan Stanley [3]

Core Viewpoint - The merger and restructuring of CICC with Dongxing Securities and Xinda Securities represents a significant step towards creating a competitive investment bank with complementary business strengths and enhanced capabilities in the capital market [1][2][8] Group 1: Merger Details - CICC will absorb Dongxing Securities and Xinda Securities through a share swap, with CICC issuing shares at a price of 36.91 yuan per share, Dongxing Securities at 16.14 yuan, and Xinda Securities at 19.15 yuan [2] - The share swap ratios are set at 1:0.4373 for Dongxing Securities and 1:0.5188 for Xinda Securities, with the merger not affecting CICC's control by Central Huijin [2][3] Group 2: Strategic Benefits - The merger is expected to create synergies in asset management, debt restructuring, and financial product innovation, leveraging the strengths of both CICC and the asset management companies [3][5] - The integration aims to enhance CICC's capital strength and overall service capabilities, positioning it as a leading investment bank in line with national financial development goals [6][8] Group 3: Market Reaction and Financial Impact - Following the announcement, CICC and Dongxing Securities saw their stocks hit the daily limit, while Xinda Securities rose over 6%, indicating positive market sentiment towards the merger [3] - Post-merger, CICC's projected revenue is expected to rank third in the industry, with total assets and net assets likely to place it fourth, significantly enhancing its capital strength [7]

Core Viewpoint - CICC (601995) shares rose over 4%, currently at HKD 20.22, with a trading volume of HKD 406 million, following a report from Morgan Stanley regarding its planned merger with Dongxing Securities (601198.SH) and Cinda Securities (601059.SH) through a share swap [1] Group 1: Company Performance - CICC's H-shares are expected to outperform its A-shares in the short term due to anticipated arbitrage activities in the A-share market following the merger announcement [1] - Since November 19, the average price of H-shares covered by Morgan Stanley has increased by 0.2%, while the Hang Seng Index has declined by approximately 1% [1] Group 2: Market Environment - The recovery of the Hong Kong IPO market and a more favorable market environment are expected to positively impact CICC's fee-based and investment income over the next 12 months [1] - CICC's H-share price-to-book ratio is projected to trend towards the mean, with potential merger news and market developments likely influencing stock performance in the coming year [1]

客户端 责任编辑：卢昱君 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 中金公司（03908）午后股价上涨4.32%，现报20.28港元，成交额4.35亿港元。 国泰海通发布研报称，维持中金公司(03908.HK)目标价27.20港元，对应2025年1.2xPB。12月17日，中 金公司公告换股吸收合并东兴证券、信达证券预案并将于12月18日复牌。考虑到中金公司此次并购的协 同性，以及当前券商板块估值深度调整逐步蓄势，维持"增持"评级。该行认为吸并有望显著提升综合实 力，协同效应预计主要体现在扩大客户基础和吸并资产效率提升。 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 中金公司（03908）午后股价上涨4.32%，现报20.28港元，成交额4.35亿港元。 国泰海通发布研报称，维持中金公司(03908.HK)目标价27.20港元，对应2025年1.2xPB。12月17日，中 金公司公告换股吸收合并东兴证券、信达证券预案并将于12月18日复牌。考虑到中金公司此次并购的协 同性，以及当前券商板块估值深度调整逐步蓄势，维持"增持"评级。该行认为吸并有望显著提升综合实 力，协同效应预 ...

Core Viewpoint - CICC (03908) shares rose over 4%, currently at HKD 20.22 with a trading volume of HKD 406 million, following a report from JPMorgan regarding its planned merger with Dongxing Securities (601198.SH) and Cinda Securities (601059.SH) through a share swap [1] Group 1: Company Performance - CICC's H-shares are expected to outperform its A-shares in the short term due to anticipated arbitrage activities in the A-share market following the proposed share swap [1] - Since November 19, the average price of H-shares covered by JPMorgan has increased by 0.2%, while the Hang Seng Index has declined by approximately 1% [1] Group 2: Market Environment - The recovery of the Hong Kong IPO market and a more favorable market environment are expected to positively impact CICC's fee-based and investment income over the next 12 months [1] - JPMorgan maintains that CICC's H-share price-to-book ratio will trend towards the mean, with potential merger news and market developments likely influencing stock performance in the coming year [1]

截至午间收盘，港股恒生指数涨0.65%，报25663.41点，恒生科技指数涨1.14%，报5480点，国企指数涨 0.5%，报8885.67点，红筹指数涨0.16%，报4056.3点。 大型科技股中，阿里巴巴-W涨0.76%，腾讯控股涨1.16%，京东集团-SW跌0.53%，小米集团-W涨 0.2%，网易-S涨1.51%，美团-W涨2.27%，快手-W涨0.99%，哔哩哔哩-W涨0.78%。 生物医药股普涨，药明康德涨超6%。北京时间12月18日凌晨，参议院官网显示，搭载修订版《生物安 全法案》的美国2026财年国防授权法案（2026NDAA）获通过。新版本生物安全法未具体点名任何一家 公司。有券商研究机构认为，2025年法案进展阶段性落地，行业回归中长期增量逻辑。 中资券商股走强，招商证券涨超3%。中信建投发布研报称，中金公司发布拟换股方式吸收合并东兴证 券，信达证券系汇金体系内券商牌照整合，换股吸收合并预案落地，中金为存续主体且不涉及配套募 资。合并后规模效应显著，三家机构核心能力形成协同互补，加之中金具备成熟并购经验，过往成功整 合中投证券，本次合并推进效率可期；合并之后，中金公司资本实力、区域服务能力 ...

Core Viewpoint - CICC (03908) shares rose over 4%, currently at HKD 20.22 with a trading volume of HKD 406 million, following the announcement of a stock-swap merger with Dongxing Securities (601198.SH) and Cinda Securities (601059.SH) [1] Group 1: Company Performance - CICC's H-shares are expected to outperform its A-shares in the short term due to anticipated arbitrage activities in the A-share market [1] - Since November 19, the average price of H-shares covered by Morgan Stanley has increased by 0.2%, while the Hang Seng Index has declined by approximately 1% [1] Group 2: Market Outlook - The recovery of the Hong Kong IPO market and a more favorable market environment are expected to positively impact CICC's fee-based and investment income over the next 12 months [1] - CICC's H-share price-to-book ratio is projected to trend towards the mean, with potential merger news and market developments likely influencing stock performance in the coming year [1]

12月19日消息，港股三大指数集体上涨。截至午间收盘，恒生指数涨0.65%，报25663.41点，恒生科技 指数涨1.14%，国企指数涨0.50%。盘面上，科网股涨多跌少，美团涨超2%，网易、百度、腾讯涨超 1%，联想跌超1%；生物医药股普涨，药明康德涨超6%；中资券商股走强，招商证券涨超3%；智能驾 驶概念股活跃，佑驾创新涨超12%；今日智汇矿业、希迪智驾上市，智汇矿业涨超111%，希迪智驾跌 超8%。 | 名称 | | 量新价 | 涨跌幅 √ | | --- | --- | --- | --- | | 恒生科技指数 | N | 5480.00 | +1.14% | | 800700 | | | | | 恒生指数 | NV | 25663.41 | +0.65% | | 800000 | | | | | 国企指数 | Nº M | 8885.67 | +0.50% | | 800100 | | | | 生物医药股普涨，药明康德涨超6%。北京时间12月18日凌晨，参议院官网显示，搭载修订版《生物安 全法案》的美国2026财年国防授权法案（2026NDAA）获通过。新版本生物安全法未具体点名任何一家 公司。有券 ...

Core Viewpoint - SenSong International (02155) has seen a significant increase in stock price, rising over 8% and currently trading at 9.08 HKD, with a trading volume of 22.42 million HKD. This surge is attributed to positive industry forecasts regarding the pharmaceutical sector and the company's strategic positioning in high-end pressure equipment [1]. Group 1: Industry Insights - According to Cinda Securities, the domestic market is expected to return to rationality starting in the second half of 2024, with gross margins gradually recovering to reasonable levels [1]. - The recovery in innovative drug financing and frequent BD transactions are driving a resurgence in Contract Manufacturing Organizations (CMOs), which is anticipated to positively impact the pharmaceutical equipment industry, suggesting a cyclical turnaround [1]. - Global strategic security backups and commitments from multinational pharmaceutical companies (MNCs) to invest domestically in the U.S. are expected to accelerate fixed asset expenditures in the pharmaceutical sector over the next three years [1]. Group 2: Company Performance - SenSong International is positioned as a leader in high-end pressure equipment, benefiting from the recovery in pharmaceutical industry capital expenditures (CAPEX) and the expansion demands from overseas MNCs [1]. - The company has experienced rapid growth in new orders, aided by the release of additional capacity in Malaysia and the acquisition of PharmaDo and BioEnhance, which strengthen its biopharmaceutical capabilities [1]. - The implementation of the "MVP" digital solution is driving significant performance growth for SenSong International [1].

Macro Strategy - The report highlights that export control measures on key metals have become a crucial advantage for China in the context of major power competition, particularly against the US and EU [10][11] - China's leading position in key metals is attributed not only to resource advantages but also to a complete industrial system that is difficult for developed economies to replicate [10][11] Fixed Income - The report indicates that the bond market is expected to face challenges in 2026, with less likelihood of a unilateral decline in interest rates as seen from 2022 to 2024, suggesting a need for a more flexible approach to bond trading [12][13] - Recent meetings have emphasized a continuation of proactive fiscal and moderately loose monetary policies, which are expected to influence bond market sentiment positively [12][13] Industry Analysis - The report discusses the merger of CICC with Dongxing and Xinda, which is expected to create a company with total assets exceeding one trillion yuan, ranking fourth in the industry [21][23] - The merger is seen as a strategic move to enhance scale and comprehensive strength in the securities industry, with large brokers expected to fill gaps through acquisitions while smaller brokers may achieve rapid growth through external mergers [21][23] Recommended Stocks - The report recommends investing in StarRing Technology, which is positioned as a leader in AI and big data infrastructure, with expected revenues of 426 million, 488 million, and 583 million yuan for 2025, 2026, and 2027 respectively [23][24] - The company is noted for its innovative GPU-Native database, which is anticipated to benefit significantly from the growing demand for AI inference [23][24]